The extensive body of evidence of TAL1 participation in the development ofT-cell leukemia suggests that inhibitors of this protein, as well as inhibitorsof the associated signaling cascades, can be used as promising therapeuticagents to treat leukemia characterized by an abnormal activity of TAL1. The gene discussed is TAL1; the disease is leukemia.